Observation and consideration on using of JAKi in clinical trials in times of COVID-19.

Yang, Jing; Al-Muriesh, Maher; Yan, Li; An, Xiangjie; Tao, Juan

Yang, Jing; Al-Muriesh, Maher; Yan, Li; An, Xiangjie; Tao, Juan.

Yang J; Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China.
Al-Muriesh M; Hubei Engineering Research Center for Skin Repair and Theranostics, Wuhan, China.
Yan L; Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China.
An X; Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China.
Tao J; Hubei Engineering Research Center for Skin Repair and Theranostics, Wuhan, China.

Dermatol Ther ; 33(6): e13831, 2020 11.

Article in English | MEDLINE | ID: covidwho-598791

Subject(s)

Alopecia Areata/drug therapy; COVID-19; Janus Kinase Inhibitors/administration & dosage; Adult; Humans; Janus Kinase Inhibitors/adverse effects; Middle Aged

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Alopecia Areata / Janus Kinase Inhibitors / COVID-19 Type of study: Case report / Observational study / Prognostic study Limits: Adult / Humans / Middle aged Language: English Journal: Dermatol Ther Journal subject: Dermatology Year: 2020 Document Type: Article Affiliation country: Dth.13831

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google